Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
- February 25, 2026
- Earnings
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview